longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Trump Just Shocked Medicare Stocks — Will Seth Klarman Seize This Moment?

benzinga_article
Jan 27, 2026 at 04:55 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Trump's proposed 0.09% rate hike for Medicare Advantage plans in 2027 led to a selloff in healthcare stocks, with major companies like CVS, Humana, Elevance, and UnitedHealth seeing significant declines. Billionaire Seth Klarman views this as a buying opportunity, increasing his stake in insurance-related stocks. Klarman believes the market is overreacting to policy changes and sees long-term value in managed care despite regulatory risks. His strategy focuses on durable businesses that can withstand market fluctuations, positioning him to capitalize on current market fears.

The Medicare Advantage trade just got repriced—by Washington. Donald Trump‘s administration proposed 0.09% rate hike for Medicare Advantage plans in 2027, a fraction of Wall Street's 4%–6% expectations, triggering a sharp selloff across the sector. Stocks of managed-care giants like CVS Health Corp (NYSE:CVS), Humana Inc (NYSE:HUM), Elevance Health Inc (NYSE:ELV), and UnitedHealth Group Inc (NYSE:UNH) plunged on Monday, and remained in the red during pre-market on Tuesday.

It was a blunt reminder that healthcare insurers don't just trade on earnings—they trade on policy. And with managed care stocks stuck in this policy-driven carnage, billionaire hedge fund manager Seth Klarman may be quietly looking to seize the moment.

Klarman's Contrarian Healthcare Bet

Baupost Group's latest filings show insurance-related stocks now make up over 16% of its disclosed U.S. equity portfolio, with Elevance Health approaching a 9% position after a 114% increase in shares. That's not a passive allocation. That's a statement.

Klarman's playbook is familiar: buy durable, cash-generating businesses when the market prices them like melting ice cubes. Rising medical utilization and regulatory uncertainty crushed managed-care multiples in 2024–2025. Klarman appears to see the sector as structurally essential—and temporarily mispriced.

He's also kept Willis Towers Watson PLC (NASDAQ:WTW) as a top holding, trimming modestly but maintaining conviction in the brokerage model. Brokers are classic Klarman "toll booth" assets: they monetize insurance volume regardless of whether premiums rise or fall.

Policy Risk vs Margin of Safety

The Medicare Advantage shock underscores the fragility of insurer margins to political decisions. More than half of Medicare beneficiaries are now in private plans, making MA a quasi-government asset class for investors. A single rate tweak can erase billions in equity value overnight.

Klarman's bet is that the market is overreacting—that scale players like Elevance retain long-term pricing power, cost control levers, and demographic tailwinds that Washington can't legislate away.

The question is whether this is deep value or a structural value trap.

Trump just reminded investors that healthcare insurers operate at the mercy of policy. Klarman is betting that fear is exactly what creates the margin of safety.

Photo: Shutterstock

Login to unlock1,909characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)
  • Apr 1, 2026 at 11:11 PMEli Lilly's Oral Weight-Loss Drug Foundayo Approved, the Only One That Can Be Taken Anytime Without Fasting
  • Mar 9, 2026 at 04:15 PMHandshake and reconciliation! Novo Nordisk withdraws lawsuit, Wegovy officially launches on the Hims & Hers platform
  • Feb 26, 2026 at 12:54 PMBeigene's Q4 revenue increased by 33% year-on-year, turning a profit for the full year, with Baiyueze achieving a record…

Related Stocks

Humana

Humana

USHUM

+2.26%

Unitedhealth

Unitedhealth

USUNH

-2.37%

CVS Health

CVS Health

USCVS

-0.66%

LongbridgeAI